Abstract:
Non-alcoholic fatty liver disease (NAFLD) is a common condition associated with obesity and metabolic syndrome, affecting approximately 25% of the global population. Our study explores the development of an effective treatment for non-alcoholic fatty liver disease (NAFLD), a condition for which there is currently no specific treatment. We studied the use of β2-agonists, such as formoterol, as a potential treatment for NAFLD, targeting lipid metabolism and inflammation. Rats fed a high-fat diet were divided into four groups: negative control, high-fat diet, treatment with formoterol, and treatment with salbutamol. Treatments were administered daily by injection for two weeks. Tissue and serum samples were analyzed to assess treatment effects. Treatment with formoterol and salbutamol significantly reduced adipose tissue weight and levels of liver enzymes (AST, ALT, GAMMA-GT), suggesting hepatic protection. β2- agonists show promising therapeutic potential for NAFLD, reducing hepatic fat accumulation and improving liver function. These findings offer prospects for future treatments targeting lipid metabolism and inflammation. Further research is needed to confirm these benefits
